Studies show Flutiform benefits for Asthma patients

According to three phase III studies presented at the 2011 European Respiratory Society Congress, the single aerosol inhaler Flutiform (fluticasone plus formoterol) from Napp Pharmaceuticals, offers a safe and efficient treatment for patients with Asthma. These studies support previous data that shows the efficacy and safety of Flutiform in adults and adolescents aged 12 years and above. As measured by lung function, Flutiform had a higher efficacy than each of its components administered seperately and was comparable in effectiveness as fluticasone and formoterol administered concurrently. Finally the studies demonstrated that the Flutiform shows comparable improvements to budesonide/formoterol in change in morning pre-dose forced expiratory volume from baseline to Week 12. Both combinations revealed similar safety profiles.